277 related articles for article (PubMed ID: 34407844)
1. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Tsimberidou AM; Shaw JV; Juric D; Verschraegen C; Weise AM; Sarantopoulos J; Lopes G; Nemunaitis J; Mita M; Park H; Ellers-Lenz B; Tian H; Xiong W; Kaleta R; Kurzrock R
J Hematol Oncol; 2021 Aug; 14(1):127. PubMed ID: 34407844
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
[TBL] [Abstract][Full Text] [Related]
3. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
DeSelm L; Huck B; Lan R; Neagu C; Potnick J; Xiao Y; Chen X; Jones R; Richardson TE; Heasley BH; Haxell T; Moore J; Tian H; Georgi K; Rohdich F; Sutton A; Johnson T; Mochalkin I; Jackson J; Lin J; Crowley L; Machl A; Clark A; Wilker E; Sherer B; Goutopoulos A
J Med Chem; 2021 Oct; 64(19):14603-14619. PubMed ID: 34596404
[TBL] [Abstract][Full Text] [Related]
4. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
Machl A; Wilker EW; Tian H; Liu X; Schroeder P; Clark A; Huck BR
Am J Cancer Res; 2016; 6(4):806-18. PubMed ID: 27186432
[TBL] [Abstract][Full Text] [Related]
5. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
Azaro A; Rodon J; Calles A; Braña I; Hidalgo M; Lopez-Casas PP; Munoz M; Westwood P; Miller J; Moser BA; Ohnmacht U; Bumgardner W; Benhadji KA; Calvo E
Invest New Drugs; 2015 Jun; 33(3):710-9. PubMed ID: 25902900
[TBL] [Abstract][Full Text] [Related]
6. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
Fukuoka S; Koga Y; Yamauchi M; Koganemaru S; Yasunaga M; Shitara K; Doi T; Yoshino T; Kuronita T; Elenbaas B; Wahra P; Zhang H; Crowley L; Jenkins MH; Clark A; Kojima T
Sci Rep; 2023 Sep; 13(1):16017. PubMed ID: 37749105
[TBL] [Abstract][Full Text] [Related]
7. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
Hong DS; Henary H; Falchook GS; Naing A; Fu S; Moulder S; Wheler JJ; Tsimberidou A; Durand JB; Khan R; Yang P; Johansen M; Newman RA; Kurzrock R
Invest New Drugs; 2014 Dec; 32(6):1204-12. PubMed ID: 24919855
[TBL] [Abstract][Full Text] [Related]
9. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C; Sfumato P; Isambert N; Dalenc F; Robert M; Levy C; Rezai K; Provansal M; Adélaïde J; Garnier S; Guille A; Carbuccia N; Popovici C; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Pakradouni J; Bertucci F; Boher JM; Sabatier R; Gonçalves A
Eur J Cancer; 2021 Dec; 159():205-214. PubMed ID: 34781168
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
[TBL] [Abstract][Full Text] [Related]
12. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
16. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Hudis C; Swanton C; Janjigian YY; Lee R; Sutherland S; Lehman R; Chandarlapaty S; Hamilton N; Gajria D; Knowles J; Shah J; Shannon K; Tetteh E; Sullivan DM; Moreno C; Yan L; Han HS
Breast Cancer Res; 2013 Nov; 15(6):R110. PubMed ID: 24252402
[TBL] [Abstract][Full Text] [Related]
18. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
19. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
20. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
